Canaccord Genuity Raises PT and Estimates on Edwards Lifesciences (EW); Preview of Cohort A Panel

June 7, 2012 8:56 AM EDT Send to a Friend
Get Alerts EW Hot Sheet
Price: $133.56 +1.64%

Rating Summary:
    16 Buy, 14 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 28 | New: 51
Trade EW Now!
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Edwards Lifesciences (NYSE: EW) price target of $103.00 (from $93.00).

Analyst, Jason R. Mills, said, "We expect FDA panel briefing documents for Cohort A to be posted this Monday, ahead of the Circulatory Devices panel Wednesday. We think two-year Cohort A results convincingly demonstrated that TAVI is non-inferior to SAVR in high-risk patients with severe symptomatic aortic stenosis. While we envision a typical “roller coaster” meeting, as panelists contemplate safety data and assess new data that emerged in two-year results, we would be buyers of EW heading into the Panel as we expect a favorable vote, which we do not think is fully contemplated in the stock."

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $86.34 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Add Your Comment